Global Biopharmaceuticaland Biomedicine Market, By Product Type (Biopharmaceutical, Nanomedicine,Gene Therapy, Bioinformatics, and Molecular Enzymes & Kits), By Application(Therapeutics, Diagnostics, and Research and Development) and by Region (NorthAmerica, Latin America, Europe, Asia Pacific, the Middle East, and Africa) wasvalued at US$ 358.4 Bn in 2016 and is projected to exhibit a CAGR of 9.4% overthe forecast period (2017–2025). Frequent launches and approvals of novelbiopharmaceutical products is expected to drive the market growth in the nearfuture. In 2017, Sanofi S.A. received U.S. Food and Drug Administration (FDA)approval for Dupixent (dupilumab) injection to treat adults suffering frommoderate to severe eczema (atopic dermatitis). In 2017, F. Hoffmann-La Roche AGreceived FDA approval for Hemlibra (emicizumab-kxwh), indicated to prevent andreduce bleeding incidents among children and adults suffering from haemophiliaA with factor VIII inhibitors. In 2017, Novo Nordisk A/S received the U.S. FDAapproval for REBINYN (Coagulation Factor IX (Recombinant), GlycoPEGylated)indicated for treatment and control of bleeding episodes, and perioperativemanagement of bleeding among children and adults. In 2017, Novo Nordiskreceived U.S. FDA approval for Fiasp (Insulin aspart injection). Fiasp is afast acting mealtime insulin, which is indicated to improve glycemic controlamong adults suffering from type 1 and type 2 diabetes. In 2017, SerumInstitute of India launched its Rabishield, a rabies monoclonal antibody,developed in partnership with the University of Massachusetts Medical School.In 2017, Mundipharma GmbH launched its Truxima (rituximab), a biosimilarmonoclonal antibody for the treatment of cancer, in the UK, Germany, Italy, theNetherlands, Belgium, Republic of Ireland, and Luxembourg, following authorizationby the European Medicines Agency (EMA). The launches and approvals of suchnovel biopharmaceutical and biomedicine technologies is expected to create aconducive environment for growth of the global biopharmaceutical andbiomedicine market.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/18
Browse 45 Market Data Tables and42 Figures spread through 285 Pages and in-depth TOC on Biopharmaceutical andBiomedicine Market By Product Type (Biopharmaceutical, Nano medicine, GeneTherapy, Bioinformatics, and Molecular Enzymes & Kits Market) and Region(North America, Latin America, Europe, Asia Pacific, the Middle East, andAfrica) - Global Forecast to 2025
Strategic collaboration of keyplayers and research institutes in the market for the development ofbiopharmaceutical and biomedicine technologies is also expected to positivelyaffect the market growth. For instance, in February 2018, AbbVie Inc. andVoyager Therapeutics, Inc. entered into a strategic partnership for thedevelopment and commercialization of gene therapies for Alzheimer's disease andother neurodegenerative diseases. In February 2018, Kite Pharma, Inc., a GileadSciences, Inc. company, collaborated with Sangamo Therapeutics Inc. fordeveloping engineered cell therapies to treat cancer. As per the agreement,Kite Pharma, Inc. will use Sangamo Therapeutics’ zinc finger nuclease (ZFN)gene-editing product type for developing next-generation ex vivo cell therapiesfor treatment of cancer. In 2017, The National Institutes of Health collaboratedwith 11 leading biopharmaceutical companies to boost the development of newcancer immunotherapy. The partners include AbbVie Inc., Amgen Inc., BoehringerIngelheim Pharma GmbH & Co. KG, Bristol-Myers Squibb, Celgene Corporation,Genentech Inc., subsidiary of Roche Group, Gilead Sciences, Inc.,GlaxoSmithKline Plc., Janssen Pharmaceutical Companies of Johnson &Johnson, Novartis A.G., and Pfizer, Inc. In 2017, AbCellera Biologics, Inc.collaborated with GlaxoSmithKline plc. for the discovery of monoclonalantibodies against an undisclosed membrane protein target.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/bio-pharmaceuticals-and-biomedicine-market-18
Key Takeaways of theBiopharmaceutical and Biomedicine Market:
The global biopharmaceutical andbiomedicine market is expected to exhibit a CAGR of 9.4% over the forecastperiod (2017–2025), owing to increasing development of novel technologies andstrategic collaboration of key players in the market for biopharmaceutical andbiomedicine technologies
North America was the dominantregion in the global biopharmaceutical and biomedicine market and is expectedto retain its dominance over the forecast period (2017–2025). This is due topresence of major key players and increasing funding by various organizationsto support biopharmaceutical researches. For instance, in 2015, NationalInstitutes of Health (NIH) funded US$ 54 million to support emerging challengesin biomedical research. NIH has funded to launch four broad scientific Program:the Glycoscience Program, the 4D Nucleome Program, the Gabriella Miller KidsFirst Research Program, and the Science of Behavior Change Program.
Asia Pacific is expected toexhibit highest growth, with a CAGR of 15.3% over the forecast period, due toincreasing research and development in China in biopharmaceutical andbiomedicine. For instance, in 2016, Chinese scientists injected cells modifiedwith the CRISPR-Cas9 gene-editing technology in human. This is the first timein world when researchers from the Sichuan University in Chengdu insertedre-engineered cells into a lung cancer patient participating in a clinicaltrial at the West China Hospital.
Major players operating in thebiopharmaceutical and biomedicine market include Amgen Inc., F. Hoffmann-LaRoche AG, Novartis AG, Johnson & Johnson, Pfizer, Inc., Sanofi S.A., EliLilly and Company, AbbVie Inc., Novo Nordisk A/S, Bristol - Myers Squibb,NanoString Technologies, Inc., Qiagen N.V., Celgene Corporation, and AffimedN.V.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/18
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
Coherent MarketInsights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
